Breast Cancer (Clinical Trials)

Taxotere Identified as Most Active Single Agent in Cancer

Published in Cancer Weekly, February 19th, 1996

The anti-cancer agent, Taxotere (docetaxel), is the most active single agent in advanced breast cancer in patients whose cancer is resistant to or progresses during standard chemotherapy that includes agents known as anthracyclines.

Results of this research were presented at the "Management of Advanced Cancer: Patient Needs, Challenges and New Treatment Options" symposium held in Prague, Czech Republic.

"Taxotere has the highest overall response rate reported to date - 56 percent - as a single agent in the treatment of late-stage breast cancer resistant to or that progresses during chemotherapy that includes anthracyclines, one of the most commonly...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-02-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry